Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 2/20 | 0.34 |
| ▸ | TYK2 | P29597 | 3/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 5/20 | 0.33 |
| ▸ | SPR | P35270 | 1/20 | 0.33 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.32 |
| ▸ | KDM5A | P29375 | 1/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.32 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.32 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | PKMYT1 | Q99640 | 1/20 | 0.31 |
| ▸ | IKBKB | O14920 | 1/20 | 0.31 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18527226 | 0.82 | NTRK1 (0.40) | PDE2ANTRK1CHRNA7ALDH1A1 | |
| SCHEMBL18538092 | 0.77 | NTRK1 (0.36) | NTRK1SPRMTNR1ABRD4CHRNA7 | |
| SCHEMBL12616365 | 0.74 | ADRA2A (0.33) | NTRK1SPRBRD4ALDH1A1L3MBTL1 | |
| SCHEMBL31370721 | 0.71 | BRD4 (0.35) | MTNR1ABRD4 | |
| SCHEMBL17145183 | 0.70 | PKMYT1 (0.37) | NTRK1SPRCHRNA7PKMYT1 | |
| SCHEMBL4403649 | 0.70 | NOS3 (0.38) | MTNR1ABRD4CHRNA7PKMYT1 | |
| SCHEMBL18527355 | 0.69 | TYK2 (0.35) | TYK2NTRK1MTNR1A | |
| SCHEMBL18527151 | 0.69 | NR3C1 (0.32) | — | |
| SCHEMBL20413788 | 0.68 | ALDH1A1 (0.42) | MTNR1ABRD4ALDH1A1PKMYT1 | |
| SCHEMBL25848123 | 0.68 | HSD17B10 (0.41) | MTNR1ABRD4KDM5AKDM4CALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170050980-A1 | OXADIAZINE COMPOUNDS AND METHODS OF USE THEREOF | DENALI THERAPEUTICS, INC. | 2017-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170050980-A1 | OXADIAZINE COMPOUNDS AND METHODS OF USE THEREOF | PSEN2, SMN1; SMN2, OTC | PDE2A 935/4885TYK2 1194/4885NTRK1 1009/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.